Research Drugs Targeting Ageing Response to Recommendation
TOTAL SCORE: 10
Score
A1 (Feasibility increased by continuance of pandemic): +2
A2 (Necessity increased by covid pandemic): 0
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): +1
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): 0
D2 (Degree of measurability): 0
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): 0
D6 (Reorganisation): 0
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This proposal earns a strong +1 for both resourcefulness (D5) and market readiness (C3). The weakness of many industrial strategies globally is that a lack of cross-sector input (a value also earning this recommendation a +1) often leads strategists unaware of when and when not to innovate. The repurposing of existing drugs is a long term strategy favoured by Aging Analytics Agency and earn.
RECOMMENDATION SUMMARY
“We recommend that UK Research and Innovation and the National Institute for Health Research support further research into drugs that target the ageing process — including proof of concept trials using repurposed drugs (such as in the TAME trial). (Paragraph 179)”
Score
A1 (Feasibility increased by continuance of pandemic): +2
A2 (Necessity increased by covid pandemic): 0
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): +1
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): 0
D2 (Degree of measurability): 0
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): 0
D6 (Reorganisation): 0
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This proposal earns a strong +1 for both resourcefulness (D5) and market readiness (C3). The weakness of many industrial strategies globally is that a lack of cross-sector input (a value also earning this recommendation a +1) often leads strategists unaware of when and when not to innovate. The repurposing of existing drugs is a long term strategy favoured by Aging Analytics Agency and earn.
RECOMMENDATION SUMMARY
“We recommend that UK Research and Innovation and the National Institute for Health Research support further research into drugs that target the ageing process — including proof of concept trials using repurposed drugs (such as in the TAME trial). (Paragraph 179)”